Overview
View Archive

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is supported by an education grant from Karyopharm Therapeutics, Inc.

Oncology Best Practice™: Matching Evidence to Practical Application For XPO1 Inhibition Strategies in Your R/R DLBCL and Myeloma Clinical Practices

Oncology Best Practice™: Matching Evidence to Practical Application For XPO1 Inhibition Strategies in Your R/R DLBCL and Myeloma Clinical Practices


Oncology Best Practice™: Matching Evidence to Practical Application For XPO1 Inhibition Strategies in Your R/R DLBCL and Myeloma Clinical Practices

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

Overview

Oncology Best Practice™ is a nationwide series of live, regional activities held in locations across the US that are deemed to have the highest educational need. This educational series will focus on the incorporation of recent practice-changing evidence on novel nuclear exportin (XPO) inhibition as a treatment strategy for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) or relapsed/refractory multiple myeloma (R/R MM) who have been exposed to multiple lines of treatment. The activity will use a variety of teaching modalities, including didactic presentation of new data, clinical scenarios exploring how novel XPO inhibitors may improve patient care, supportive care measures for patients with hematologic malignancies who have been exposed to multiple rounds of cancer therapy, real-world cases that challenge learners to reflect on the application of the evidence to their own clinical practices, and peer-to-peer and peer-to-expert interactions. We look forward to you joining us to learn how to bring the latest innovative cancer treatment strategies to your patients.

Benefits of Attending

  • Enjoy an evening of direct interaction with world-renowned experts in R/R DLBCL and R/R MM
  • Explore how XPO inhibitors are currently being used by experts managing heavily pretreated patients with R/R DLBCL or R/R MM
  • Learn how the experts and your peers are managing challenging cases of patients with heavily pretreated R/R DLBCL or R/R MM
  • Review supportive care measures for patients with hematologic malignancies who have been exposed to multiple rounds of cancer therapy

Target Audience

This activity is directed toward medical oncologists and hematologist/oncologists who treat or manage patients with hematologic malignancies. Other oncology health care professionals, including nurses and pharmacists who manage patients with hematologic malignancies, are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the rationale for the application of XPO inhibitory strategies in hematologic malignancy settings
  • Explain the impact of risk stratification and treatment resistance on decision-making for patients with R/R DLBCL or R/R MM
  • Examine efficacy and safety results from clinical trials conducted among patients with R/R DLBCL or R/R MM that have evaluated XPO inhibition strategies
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By